Common blood thinner for pregnant women proven ineffective
A daily injection to the belly commonly prescribed for pregnant women at risk of developing blood clots is found to be ineffective. As many as one in 10 pregnant women have a tendency to develop blood clots in their veins, a condition called thrombophilia. The anticoagulant LMWH has been prescribed for two decades to prevent related pregnancy complications. Now, a study provides conclusive evidence that it has no positive benefits for the mother or child, and could actually cause pregnant women some minor harm.
It’s a daily injection to the belly for pregnant women at risk of developing blood clots and it’s ineffective, according to a clinical trial led by researchers at The Ottawa Hospital and published today by the medical journal The Lancet.As many as one in 10 pregnant women have a tendency to develop blood clots in their veins, a condition called thrombophilia. For two decades these women have often been prescribed the anticoagulant low molecular weight heparin (LMWH) to prevent pregnancy complications caused by placental blood clots. This treatment requires women to give themselves daily injections — a painful and demoralizing process that requires women to poke their abdomen with hundreds of needles over the course of their pregnancy.Now, a randomized clinical trial led by Dr. Marc Rodger, a senior scientist at the Ottawa Hospital Research Institute who heads up the Thrombosis Program of The Ottawa Hospital, provides conclusive evidence that the commonly prescribed LMWH anticoagulant has no positive benefits for the mother or child. In fact, Dr. Rodger’s study shows that LMWH treatments could actually cause pregnant women some minor harm by increasing bleeding, increasing their rates of induced labour and reducing their access to anesthesia during childbirth.”These results mean that many women around the world can save themselves a lot of unnecessary pain during pregnancy,” says Dr. Rodger, who is also a professor in the Faculty of Medicine at the University of Ottawa. “Using low molecular weight heparin unnecessarily medicalizes a woman’s pregnancy and is costly.”Since the 1990s, using LMWH to treat pregnant women with a tendency to develop blood clots became commonplace, despite the fact that a large, multi-site randomized clinical trial had never been conducted to prove its effectiveness. Low molecular weight heparin is also prescribed by many physicians worldwide to women, with and without thrombophilia, to prevent placenta blood clots that may lead to pregnancy loss, as well as preeclampsia (high blood pressure), placental abruption (heavy bleeding) and intra-uterine growth restrictions (low birth weight babies). The anticoagulant LMWH is also prescribed to prevent deep vein thrombosis (leg vein blood clots) and pulmonary embolisms (lung blood clots).”While I wish we could have shown that LMWH prevents complications, we actually proved it doesn’t help,” adds Dr. …
For more info: Common blood thinner for pregnant women proven ineffective